ea0089b4 | Basic Science | NANETS2022
Whitt Jason
, Houson Hailey
, Guenter Rachael
, Murphy Madisen
, Lapi Suzanne
, Jaskula-Sztul Renata
Background: Neuroendocrine tumor (NET) patients with diminished SSTR2 expre-ssion are not eligible for any type of SSTR2-specific imaging or treatment. Herein, we propose to epigenetically enhance and enable somatostatin receptor type 2 (SSTR2)-targeted theranostics for patients with NETs. Specifically, we have found that simultaneous inhibition of DNA methylation and his-tone de-ace-tylation enhanced SSTR2 expression and in vitro binding of [68Ga]DOTATATE....